Log in

Cyclacel Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:CYCC)

$0.39
+0.02 (+5.41 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$0.37
Now: $0.39
$0.40
50-Day Range
$0.33
MA: $0.38
$0.43
52-Week Range
$0.28
Now: $0.39
$1.20
Volume27,400 shs
Average Volume48,996 shs
Market Capitalization$6.71 million
P/E RatioN/A
Dividend YieldN/A
Beta3
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYCC
CUSIPN/A
Phone908-517-7330

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$0.81 per share

Profitability

Net Income$-7,290,000.00

Miscellaneous

Employees14
Market Cap$6.71 million
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable

Receive CYCC News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.


Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Cyclacel Pharmaceuticals shares reverse split on the morning of Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) posted its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.04. View Cyclacel Pharmaceuticals' Earnings History.

When is Cyclacel Pharmaceuticals' next earnings date?

Cyclacel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Cyclacel Pharmaceuticals.

What is the consensus analysts' recommendation for Cyclacel Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cyclacel Pharmaceuticals.

Has Cyclacel Pharmaceuticals been receiving favorable news coverage?

News stories about CYCC stock have been trending somewhat positive on Sunday, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cyclacel Pharmaceuticals earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the stock's share price in the immediate future. View News Stories for Cyclacel Pharmaceuticals.

Who are some of Cyclacel Pharmaceuticals' key competitors?

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the folowing people:
  • Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 60)
  • Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 58)
  • Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 59)
  • Ms. Gill Christie, Director of HR (Age 62)
  • Dr. Robert Westwood Ph.D., Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. (Age 75)

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $0.39.

How big of a company is Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals has a market capitalization of $6.71 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-7,290,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Cyclacel Pharmaceuticals employs 14 workers across the globe.View Additional Information About Cyclacel Pharmaceuticals.

What is Cyclacel Pharmaceuticals' official website?

The official website for Cyclacel Pharmaceuticals is http://www.cyclacel.com/.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]


MarketBeat Community Rating for Cyclacel Pharmaceuticals (NASDAQ CYCC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  322
MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote "Outperform" if you believe CYCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel